Why Aduhelm, a new Alzheimer's treatment, isn't reaching many patients
10 min•5 november 2021
Aduhelm, known generically as aducanumab, is the first drug to actually affect the underlying disease process associated with Alzheimer's. Yet sales have been limited, and the drug is reaching very few patients — at least so far. It's expensive, risky and likely doing little to improve patients' lives. NPR science correspondent Jon Hamilton explains why doctors and patients aren't excited about the new drug and what it could mean for future Alzheimer's drugs.
Additional links:
- Jon's reporting on aducanumab: https://n.pr/3bDV0MY
- Jon's reporting on future Alzheimer's treatments: https://n.pr/3bDUsqo
You can always reach the show by emailing [email protected].
To manage podcast ad preferences, review the links below:
See pcm.adswizz.com for information about our collection and use of personal data for sponsorship and to manage your podcast sponsorship preferences.
NPR Privacy Policy
Additional links:
- Jon's reporting on aducanumab: https://n.pr/3bDV0MY
- Jon's reporting on future Alzheimer's treatments: https://n.pr/3bDUsqo
You can always reach the show by emailing [email protected].
To manage podcast ad preferences, review the links below:
See pcm.adswizz.com for information about our collection and use of personal data for sponsorship and to manage your podcast sponsorship preferences.
NPR Privacy Policy
Fler avsnitt av Short Wave
Visa alla avsnitt av Short WaveShort Wave med NPR finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.